Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aEC): Subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors Meeting Abstract
| Authors: | Makker, V.; Colombo, N.; Casado Herráez, A.; Santin, A.; Colomba, E.; Miller, D.; Fujiwara, K.; Pignata, S.; Banerjee, S.; Monk, B.; Ushijima, K.; Penson, R.; Kristeleit, R.; Fabbro, M.; Orlando, M.; Mackay, H.; Ren, M.; Orlowski, R.; Dutta, L.; Lorusso, D. |
| Abstract Title: | Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aEC): Subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors |
| Meeting Title: | IGCS 2021 Annual Meeting |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2021 Aug 30-Sep 2 |
| Meeting Location: | Virtual |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2021-11-01 |
| Start Page: | A1 |
| End Page: | A2 |
| Language: | English |
| ACCESSION: | WOS:000773625600003 |
| DOI: | 10.1136/ijgc-2021-IGCS.2 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: O002/#43 -- Source: Wos |
